MCID: SNS003
MIFTS: 45

Sensory Peripheral Neuropathy malady

Categories: Neuronal diseases

Aliases & Classifications for Sensory Peripheral Neuropathy

Aliases & Descriptions for Sensory Peripheral Neuropathy:

Name: Sensory Peripheral Neuropathy 12 14
Sensory Neuropathy 12 29 52 14 69
Hereditary Sensory and Autonomic Neuropathies 42 69
Peripheral Sensory Neuropathy 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2491
ICD9CM 35 356.2
MeSH 42 D009477
NCIt 47 C3501

Summaries for Sensory Peripheral Neuropathy

Disease Ontology : 12 A neuropathy that involves damage to nerves of the peripheral nervous system.

MalaCards based summary : Sensory Peripheral Neuropathy, also known as sensory neuropathy, is related to hereditary motor and sensory neuropathy via and hereditary sensory and autonomic neuropathy type 1e, and has symptoms including hyperesthesia, sciatica and neurologic symptoms. An important gene associated with Sensory Peripheral Neuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are Brain-Derived Neurotrophic Factor (BDNF) signaling pathway and Guidance Cues and Growth Cone Motility. The drugs Ziconotide and Etoricoxib have been mentioned in the context of this disorder. Related phenotypes are Increased shRNA abundance (Z-score > 2) and behavior/neurological

Related Diseases for Sensory Peripheral Neuropathy

Diseases related to Sensory Peripheral Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 67)
id Related Disease Score Top Affiliating Genes
1 hereditary motor and sensory neuropathy via 33.7 MFN2 PMP22
2 hereditary sensory and autonomic neuropathy type 1e 12.4
3 hereditary sensory neuropathy 12.3
4 hereditary motor and sensory neuropathy v 12.2
5 hereditary sensory and autonomic neuropathy type iic 12.2
6 deafness, x-linked 5 11.2
7 charcot-marie-tooth disease, type 2b 11.1
8 spinocerebellar ataxia, autosomal recessive 16 11.0
9 x-linked hereditary sensory and autonomic neuropathy with deafness 11.0
10 cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia 10.9
11 charcot-marie-tooth neuropathy, x-linked dominant, 1 10.9
12 ataxia, posterior column, with retinitis pigmentosa 10.9
13 craniorachischisis 10.3 MPZ PMP22
14 hypertonia 10.3 MPZ PMP22
15 severe intellectual disability-progressive spastic diplegia syndrome 10.3 GJB1 SPTLC1
16 williams-beuren syndrome 10.3 GJB1 MPZ
17 neuropathy 10.2
18 surfactant metabolism dysfunction, pulmonary, 2 10.2 GJB1 MPZ PMP22
19 acute sanguinous otitis media 10.2 GJB1 MPZ PMP22
20 short stature, idiopathic familial 10.2 GDAP1 MTMR2
21 spermatogenic failure, x-linked, 2 10.2 GDAP1 GJB1 MPZ
22 pituitary adenoma, prolactin-secreting 10.2 MFN2 MPZ PMP22
23 mohr-tranebjaerg syndrome 10.2 MAG MPZ PMP22
24 status epilepticus 10.2 MAG MPZ PMP22
25 hypermobility of coccyx 10.2 NGF PMP22
26 yunis-varon syndrome 10.2 GDAP1 MTMR2
27 white piedra 10.1 MAG MPZ PMP22
28 glomangiosarcoma 10.1 MAG PMP22
29 gnathodiaphyseal dysplasia 10.1 GDAP1 MTMR2 PRX
30 charcot-marie-tooth disease, axonal, type 2k 10.1 GDAP1 MTMR2 PRX
31 deafness, autosomal dominant 8/12 10.1 GDAP1 MTMR2 PRX
32 hereditary type 2 neuropathy 10.1 LITAF MPZ PMP22
33 pneumonic plague 10.1 GJB1 MPZ PMP22 PRX
34 aortic valve prolapse 10.1 MAG NGF PMP22
35 fissured tongue 10.0 NGF NTF3 SPTLC1
36 aortic aneurysm, familial thoracic 4 10.0 LITAF MPZ
37 rickets due to defect in vitamin d 25-hydroxylation 10.0 MAG MPZ
38 bladder lateral wall cancer 10.0 EGR2 PMP22
39 dejerine-sottas disease 10.0 GDAP1 GJB1 MFN2 MPZ PMP22
40 childhood infratentorial neoplasm 10.0 LITAF PMP22
41 thrombophilia due to antithrombin iii deficiency 10.0 GDAP1 GJB1 MFN2 MPZ PMP22
42 dilated cardiomyopathy 10.0 MPZ NGF NTF3 PMP22
43 charcot-marie-tooth disease, type 1e 9.9 EGR2 GJB1 MPZ PMP22
44 genitopatellar syndrome 9.9 EGR2 NDRG1
45 substance-induced psychosis 9.9 GJB1 MAG MPZ NGF PMP22
46 conotruncal heart malformations 9.9 GDAP1 GJB1 MFN2 MPZ MTMR2 PMP22
47 parastremmatic dwarfism 9.9 GDAP1 GJB1 MFN2 MPZ NDRG1
48 5-oxoprolinase deficiency 9.8 GDAP1 GJB1 MFN2 NDRG1 NTF3
49 hypertrophic osteoarthropathy, primary, autosomal recessive 2 9.8 EGR2 GJB1 MPZ PMP22 SPTLC1
50 chrna1-related congenital myasthenic syndrome 9.8 EGR2 GJB1 MPZ PMP22 PRX

Graphical network of the top 20 diseases related to Sensory Peripheral Neuropathy:



Diseases related to Sensory Peripheral Neuropathy

Symptoms & Phenotypes for Sensory Peripheral Neuropathy

UMLS symptoms related to Sensory Peripheral Neuropathy:


hyperesthesia, sciatica, neurologic symptoms, dysesthesia

GenomeRNAi Phenotypes related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.87 FGD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.87 FGD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.87 SLC12A6
4 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.87 NTF3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.87 FGD4 GJB1 NTF3 SLC12A6
6 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.87 NTF3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.87 FGD4
8 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.87 FGD4
9 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.87 GJB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.87 FGD4
11 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.87 NTF3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.87 GJB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.87 GJB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.87 SLC12A6
15 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.87 NTF3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-205 9.87 FGD4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.87 GJB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.87 SLC12A6
19 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.87 GJB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-215 9.87 SLC12A6
21 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.87 SLC12A6
22 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.87 SLC12A6
23 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.87 SLC12A6
24 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.87 GJB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-51 9.87 GJB1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.87 FGD4
27 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.87 NTF3
28 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.87 SLC12A6
29 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.87 SLC12A6
30 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.87 NTF3
31 Increased shRNA abundance (Z-score > 2) GR00366-A-92 9.87 FGD4
32 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.87 SLC12A6

MGI Mouse Phenotypes related to Sensory Peripheral Neuropathy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.31 EGR2 FGD4 GDAP1 GJB1 MAG MFN2
2 growth/size/body region MP:0005378 10.11 EGR2 FLVCR1 GJB1 MFN2 MTMR2 NDRG1
3 homeostasis/metabolism MP:0005376 10.1 FLVCR1 GDAP1 GJB1 LITAF MAG MFN2
4 cellular MP:0005384 10.06 EGR2 GDAP1 GJB1 LITAF MFN2 MPZ
5 nervous system MP:0003631 10.06 LITAF MAG MFN2 MPZ MTMR2 NDRG1
6 mortality/aging MP:0010768 10 EGR2 FLVCR1 GJB1 MFN2 MPZ MTMR2
7 reproductive system MP:0005389 9.56 EGR2 FLVCR1 SLC12A6 SPTLC1 MPZ MTMR2
8 vision/eye MP:0005391 9.17 EGR2 GJB1 NDRG1 NGF NTF3 PMP22

Drugs & Therapeutics for Sensory Peripheral Neuropathy

Drugs for Sensory Peripheral Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 489)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ziconotide Approved Phase 4,Phase 2 107452-89-1 447451
2
Etoricoxib Approved, Investigational Phase 4,Phase 2 202409-33-4 123619
3
Fexofenadine Approved Phase 4 83799-24-0 3348
4
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 60142-96-3 3446
5
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
6
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 148553-50-8 5486971
7
Imipramine Approved Phase 4 50-49-7 3696
8
Capsaicin Approved Phase 4,Phase 2,Phase 3,Phase 1 404-86-4 1548943
9
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2 6740-88-1 3821
10
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2 15307-86-5 3033
11
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 137-58-6 3676
12
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2180-92-9, 38396-39-3 2474
13
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
14
Levobupivacaine Approved Phase 4,Phase 3 27262-47-1 92253
15
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 76-42-6 5284603
16
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
17
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
18
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-41-2 439260
19
Acetaminophen Approved Phase 4,Phase 3,Phase 2 103-90-2 1983
20
Amitriptyline Approved Phase 4,Phase 3,Phase 2 50-48-6 2160
21
Carbamazepine Approved, Investigational Phase 4,Phase 2,Phase 3 298-46-4 2554
22
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
23
Perphenazine Approved Phase 4,Phase 3,Phase 2 58-39-9 4748
24
Oxcarbazepine Approved Phase 4 28721-07-5 34312
25
Midazolam Approved, Illicit Phase 4,Phase 2 59467-70-8 4192
26
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2 1972-08-3 16078 2978
27
Nabilone Approved, Investigational Phase 4,Phase 3,Phase 2 51022-71-0 5284592
28
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
29
Remifentanil Approved Phase 4,Phase 3 132875-61-7 60815
30
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
31
Propranolol Approved, Investigational Phase 4 525-66-6 4946
32
Hydroxocobalamin Approved Phase 4,Phase 3 13422-51-0 11953898 5460373 44475014
33
Ropivacaine Approved Phase 4,Phase 2 84057-95-4 71273 175805
34
Naloxone Approved, Vet_approved Phase 4,Phase 2 465-65-6 5284596
35
Citalopram Approved Phase 4 59729-33-8 2771
36
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2 27203-92-5 33741
37
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 83-43-2 6741
38
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 50-24-8 5755
39
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 5281106 54677470
40
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
41
Methadone Approved Phase 4,Phase 3,Phase 2 76-99-3 4095
42
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 124-94-7 31307
43
Minocycline Approved, Investigational Phase 4,Phase 2 10118-90-8 5281021
44
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
45
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2 76631-46-4, 113775-47-6 68602 5311068 56032
46
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
47
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
48
Mexiletine Approved Phase 4,Phase 2 31828-71-4 4178
49
Nortriptyline Approved Phase 4,Phase 2 72-69-5 4543
50
Ibuprofen Approved Phase 4,Phase 2,Phase 3 15687-27-1 3672

Interventional clinical trials:

(show top 50) (show all 752)
id Name Status NCT ID Phase
1 Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy Unknown status NCT01992562 Phase 4
2 Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain Unknown status NCT01264237 Phase 4
3 Pregabalin for the Treatment of Uremic Pruritus Unknown status NCT01852318 Phase 4
4 Effects of Pregabalin on Mechanical Hyperalgesia Unknown status NCT00310583 Phase 4
5 Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain Unknown status NCT01479556 Phase 4
6 Imipramine and Pregabalin Combination in Painful Polyneuropathy Unknown status NCT01047488 Phase 4
7 Qutenza for Critical Ischaemia in End Stage Renal Failure Unknown status NCT01704339 Phase 4
8 Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy Unknown status NCT01770964 Phase 4
9 Preventing Pain After Heart Surgery Unknown status NCT01480765 Phase 4
10 Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study) Completed NCT01458600 Phase 4
11 Anodyne Therapy in Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
12 A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4
13 Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
14 Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy Completed NCT00903851 Phase 4
15 Comparison of the Analgesic Effect of Different Local Anesthetics in Interscalene Nerve Block for Shoulder Surgery Completed NCT02691442 Phase 4
16 Frequency Modulated Neural Stimulation (FREMS) in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
17 Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4
18 A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) Completed NCT01675531 Phase 4
19 Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4
20 A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN) Completed NCT00156078 Phase 4
21 A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4
22 Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management Completed NCT01364298 Phase 4
23 Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP Completed NCT00407511 Phase 4
24 Intrathecal Bolus Doses of Ziconotide Completed NCT01373983 Phase 4
25 Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) Completed NCT00322621 Phase 4
26 A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy Completed NCT00573261 Phase 4
27 A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain Completed NCT00904020 Phase 4
28 Escitalopram as a Treatment for Pain in Polyneuropathy Completed NCT00162968 Phase 4
29 Comparison of the Efficacy of Duloxetine With Placebo in Patients With Chronic Low Back Pain With a Radicular Component Completed NCT01166048 Phase 4
30 Safety and Effectiveness of Repeated Administration of QUTENZA Patches for Treatment of Pain Caused by Nerve Damage Completed NCT01252160 Phase 4
31 A Study to Compare Safety and Efficacy of Tramadol Hydrochloride/Acetaminophen With Gabapentin in Participants With Diabetic Neuropathy Completed NCT00634543 Phase 4
32 A Study on the Efficacy and Safety of Gabapentin in the Treatment of Patients With Painful Diabetic Neuropathy Completed NCT00644748 Phase 4
33 Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies Completed NCT02842554 Phase 4
34 Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain Completed NCT00313820 Phase 4
35 An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4
36 A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment Completed NCT01713426 Phase 4
37 Postoperative Alpha Lipoic Acid in the Carpal Tunnel Syndrome: a Randomized Controlled Trial. Completed NCT01895621 Phase 4
38 Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder Completed NCT00844194 Phase 4
39 Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain Completed NCT00266643 Phase 4
40 Efficacy Study of Local Steroid Injection and Wrist Splinting for Carpal Tunnel Syndrome Completed NCT02140632 Phase 4
41 Arthroplasty Versus Fusion in Anterior Cervical Surgery: Prospective Study of the Impact on the Adjacent Level Completed NCT00554528 Phase 4
42 A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP) Completed NCT02417935 Phase 4
43 Efficacy and Tolerability of Carbamazepine CR in Diabetic Neuropathy Pain Completed NCT01089855 Phase 4
44 Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain Completed NCT01207596 Phase 4
45 Methadone and Ketamine for Neuropathic Pain Treatment Completed NCT02233452 Phase 4
46 NEP-TUNE: Neuropathic Pain - Treatment With Pregabalin Under Real-life Conditions in Denmark Completed NCT01524796 Phase 4
47 Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN) Completed NCT01455428 Phase 4
48 A Post Marketing Surveillance Study On Pregabalin (Lyrica) On Efficacy, Safety And Tolerability Of Pregabalin Completed NCT00892008 Phase 4
49 Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA Completed NCT00843284 Phase 4
50 P4 (Pregabalin for Peripheral Posttraumatic Pain) Completed NCT00292188 Phase 4

Search NIH Clinical Center for Sensory Peripheral Neuropathy

Cochrane evidence based reviews: hereditary sensory and autonomic neuropathies

Genetic Tests for Sensory Peripheral Neuropathy

Genetic tests related to Sensory Peripheral Neuropathy:

id Genetic test Affiliating Genes
1 Sensory Neuropathy 29

Anatomical Context for Sensory Peripheral Neuropathy

Publications for Sensory Peripheral Neuropathy

Articles related to Sensory Peripheral Neuropathy:

(show all 14)
id Title Authors Year
1
Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy. ( 26015512 )
2015
2
Pain, sleep disturbances, and functional limitations in people living with HIV/AIDS-associated distal sensory peripheral neuropathy. ( 25513029 )
2014
3
Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). ( 24513692 )
2014
4
Acu/Moxa for distal sensory peripheral neuropathy in HIV: a randomized control pilot study. ( 23582399 )
2013
5
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. ( 23204130 )
2013
6
Pain, Sleep Disturbances, and Functional Limitations in People Living with HIV/AIDS-Associated Distal Sensory Peripheral Neuropathy. ( 23887924 )
2013
7
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. ( 22843789 )
2012
8
Relation of sensory peripheral neuropathy in SjAPgren syndrome to anti-Ro/SSA. ( 22955477 )
2012
9
Lack of motor progression in isolated sensory peripheral neuropathy. ( 20724263 )
2010
10
Reversible motor and sensory peripheral neuropathy in a patient following acute carbon monoxide intoxication. ( 15773259 )
2005
11
Screening for distal sensory peripheral neuropathy in HIV-infected persons in research and clinical settings. ( 9855522 )
1998
12
[Chronic hexosaminidase A deficiency associated with pure sensory peripheral neuropathy]. ( 1302293 )
1992
13
Sensory peripheral neuropathy of vitamin B12 deficiency: a primary demyelinating disease? ( 2835439 )
1988
14
Subepidermal vesicular dermatosis and sensory peripheral neuropathy caused by pyridoxine abuse. ( 3011864 )
1986

Variations for Sensory Peripheral Neuropathy

ClinVar genetic disease variations for Sensory Peripheral Neuropathy:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 GDAP1 NM_018972.2(GDAP1): c.715C> T (p.Leu239Phe) single nucleotide variant Pathogenic rs104894080 GRCh37 Chromosome 8, 75276240: 75276240
2 MPZ NM_000530.7(MPZ): c.293G> A (p.Arg98His) single nucleotide variant Pathogenic/Likely pathogenic rs121913589 GRCh37 Chromosome 1, 161276653: 161276653

Expression for Sensory Peripheral Neuropathy

Search GEO for disease gene expression data for Sensory Peripheral Neuropathy.

Pathways for Sensory Peripheral Neuropathy

Pathways related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.59 EGR2 NGF NTF3
2 11.4 GDAP1 MAG NGF
3 11.14 GJB1 MPZ PMP22
4
Show member pathways
10.62 MAG NGF NTF3

GO Terms for Sensory Peripheral Neuropathy

Cellular components related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 9.13 MAG MPZ NDRG1
2 compact myelin GO:0043218 8.62 MAG PMP22

Biological processes related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of neuron apoptotic process GO:0043524 9.43 MAG NGF NTF3
2 regulation of neuron differentiation GO:0045664 9.37 NGF NTF3
3 peripheral nervous system development GO:0007422 9.32 EGR2 PMP22
4 mitochondrial fusion GO:0008053 9.16 GDAP1 MFN2
5 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 8.96 MAG MPZ
6 myelination GO:0042552 8.8 EGR2 MPZ PMP22

Sources for Sensory Peripheral Neuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....